EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission

Hideaki Bando, Toshihiro Misumi, Yasutoshi Sakamoto, Yuriko Takeda, Yoshiaki Nakamura, Kazuya Mizuguchi, Yoshihiro Aoyagi, Izumi Miki, Tomohiro Kuroda, Ryu Kasai, Takuya Suzuki, Takayuki Yoshino und 1 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.04.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Hideaki Bando und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Dev…. Hauptthemen laut MEDLINE: Databases, Factual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Chugai Pharmaceuticals Co Ltd, Eisai Co Ltd, Eisai Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extraction of data that contribute to regulatory approval from real-world data (RWD) is difficult because of the lack of a standardized data format and extraction methodology. Additionally, when real-world evidence (RWE) is used as an external control group, the similarity between internal and external control data is not evaluated. To investigate the data extraction methodology for the external control data of rare molecular subtypes, we have initiated the "REALISE" study. In this study, we aim to elucidate the "relevance" and "reliability" of RWD/RWE necessary for regulatory approval. As most databases are not designed for regulatory use in the creation phase, we will investigate retrospective methodologies to ensure RWD/RWE reliability. This study will compare the "relevance" and "reliability" of the ARCAD global database, SCRUM-Japan Registry, SCRUM-Japan observational study, and Flatiron Health RWD, and statistically analyze the differences and similarities among the four databases. We will also examine the methodology for extracting sufficiently relevant data from the SCRUM-Japan observational study. Additionally, if the reliability of the RWD/RWE does not reach the required level for regulatory approval, we will examine the methodologies to ensure the "reliability" of the SCRUM-Japan observational study for regulatory approval. The obtained results will be submitted to the "Consultation for Development of Registry" in the Pharmaceuticals and Medical Devices Agency, and we will discuss the standard methodology. The procedures and findings identified in the REALISE study will be organized from the perspectives of "database construction," "data analysis," and "outcome evaluation" and will be issued as "the draft guidelines."

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Databases, FactualHumansReproducibility of ResultsRegistriesRetrospective StudiesJapanResearch Design

Stichwörter der Autor:innen

External control dataNew drug applicationRELISE studyReal-world evidenceSCRUM-Japan Registry

Autor:innen und Institutionen

  • Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan;…
  • Division of Data Science, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Medical Information, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Information Technology Management Section, Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Graduate School of Medicine, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.

Förderung

  • Chugai Pharmaceuticals Co Ltd
  • Eisai Co Ltd
  • Eisai Canada
  • Government of Japan Ministry of Health Labour and Welfare

Zitieren

APA

Bando, H., Misumi, T., Sakamoto, Y., Takeda, Y., Nakamura, Y., Mizuguchi, K., Aoyagi, Y., Miki, I., Kuroda, T., Kasai, R., Suzuki, T., Yoshino, T., & Ohtsu, A. (2024). Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.04.001

Vancouver

Bando H, Misumi T, Sakamoto Y, Takeda Y, Nakamura Y, Mizuguchi K, et al. Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.04.001

BibTeX
@article{Bando2024,
  author = {Bando, Hideaki and Misumi, Toshihiro and Sakamoto, Yasutoshi and Takeda, Yuriko and Nakamura, Yoshiaki and Mizuguchi, Kazuya and Aoyagi, Yoshihiro and Miki, Izumi and Kuroda, Tomohiro and Kasai, Ryu and Suzuki, Takuya and Yoshino, Takayuki and Ohtsu, Atsushi},
  title = {Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.04.001}
}
Kostenlos starten →